Investor Relations

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Corporate Overview

  o View Corporate Overview  
       

CEL-SCI Presentations & Interviews

  September 11, 2017
Geert Kersten at the Rodman & Renshaw 19th Annual Global Investment Conference

 
  February 2016
Geert Kersten as a featured guest on Fox Business' Making Money with Charles Payne

 
  January 2016
Interview with Dr. Eyal Talor, Chief Scientific Officer

 
  January 2016
Geert Kersten at the Noble Financial Capital Markets' 12th Annual Investor Conference

 

Warrant Quote

  o NYSE American: CVM WS  

 

Press Releases

  o All Press Releases  
 
  NOVEMBER 13, 2017
NEW STORY CEL-SCI Announces Update on Arbitration against Former Clinical Research Organization
  OCTOBER 10, 2017
NEW STORY CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making Tumors 'Visible' To the Immune System
  OCTOBER 5, 2017
NEW STORY CEL-SCI Announces Update on Ongoing Arbitration Against Former Clinical Research Organization
  SEPTEMBER 19, 2017
NEW STORY CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine
  AUGUST 29, 2017
NEW STORY CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued In December 2016
  AUGUST 23, 2017
NEW STORY CEL-SCI Announces $3.5 Million Registered Direct Offering
  AUGUST 14, 2017
NEW STORY U.S. FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial
  AUGUST 9, 2017
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results
  JUNE 12, 2017
NEW STORY CEL-SCI Announces Reverse Stock Split
  JUNE 8, 2017
NEW STORY CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com